These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34279108)

  • 1. RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2.
    Yang Z; Hua L; Yang M; Liu SQ; Shen J; Li W; Long Q; Bai H; Yang X; Ren Z; Zheng X; Sun W; Ye C; Li D; Zheng P; He J; Chen Y; Huang W; Peng X; Ma Y
    Nano Lett; 2021 Jul; 21(14):5920-5930. PubMed ID: 34279108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerized porin as a novel delivery platform for coronavirus vaccine.
    Yang Z; Hua L; Yang M; Li W; Ren Z; Zheng X; Chen H; Long Q; Bai H; Huang W; Ma Y
    J Nanobiotechnology; 2022 Jun; 20(1):260. PubMed ID: 35672856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
    J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant
    Kim BJ; Jeong H; Seo H; Lee MH; Shin HM; Kim BJ
    Front Immunol; 2021; 12():712274. PubMed ID: 34512635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection.
    Fu Y; Xiong S
    J Control Release; 2021 Jul; 335():584-595. PubMed ID: 34089793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response.
    Liu Z; Yang C; Zhang H; Cao G; Wang S; Yin S; Wang Y
    Front Immunol; 2022; 13():960094. PubMed ID: 36389744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice.
    Gao T; Ren Y; Li S; Lu X; Lei H
    Microb Cell Fact; 2021 May; 20(1):95. PubMed ID: 33952256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
    Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
    Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.